The Bitcoin Power Law, a mathematical model observed over 130 years, suggests Bitcoin's price follows a predictable growth pattern where its value increases but growth rates slow as Bitcoin ages. According to this model, Bitcoin's price could reach around $1 million by 2033, with each doubling of Bitcoin's age leading to roughly a 50-fold increase in long-term trend price. The model has explained about 96% of Bitcoin's historical price variation but has limitations, as past bull-market peaks often exceeded the trend significantly. While it serves as a useful long-term benchmark, the $1 million prediction depends on whether Bitcoin's growth pattern continues, making it more of a guide than a guaranteed forecast.
The Bitcoin Power Law and its price prediction offer context for cryptocurrency market trends. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Nov 04, 2026 05:41 WIB: out of 50 major cryptocurrencies, 39 rose and 10 fell today. Notable movers include LUNC at Rp0,74 with a 2.12% increase and a buy order activity of 58%, FTM at Rp11.382 down 2.05%, and TRX at Rp5.907 up 1.95% with 86% buy orders.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
